Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.
Acetazolamide should not be used with other carbonic anhydrase inhibitors
methazolamide (Neptazane). Use of two carbonic anhydrase inhibitors may
cause dangerously low levels of blood potassium
PREGNANCY AND BREASTFEEDING SAFETY:
There are no adequate studies evaluating the use of acetazolamide
during pregnancy. Evidence of
birth defects was observed with administration of oral
and injectable acetazolamide in mice, rats, hamsters, and rabbits. Therefore,
acetazolamide should only be used during pregnancy if the potential benefit of
treatment outweighs the potential risk to the unborn baby. Acetazolamide is
classified as FDA pregnancy risk category C.
It is not known whether acetazolamide is excreted into human milk. Because
many drugs are excreted into human milk and can cause side effects in the
nursing infant, the manufacturer recommends that patients should discontinue
nursing or discontinue acetazolamide, taking into account the importance of
treatment to the mother. However, according to the American Academy of Pediatrics, acetazolamide is usually considered to be compatible with
All oral preparations of acetazolamide should be stored at room temperature.
Before mixing, injection acetazolamide should be stored at room temperature,
between 20 C and 25 C (68 F and 77) F.
After mixing, acetazolamide injection should be stored in the refrigerator,
between 2.2 C and 7.7 C (36 F and 46 F) and used within 12 hours of mixing.